Solid Biosciences Inc., founded in the United States, is a biotechnology company dedicated to developing therapies and devices for patients with neuromuscular and cardiac diseases, with a particular focus on Duchenne muscular dystrophy. The company's core mission is to advance genetic medicines to improve the lives of those affected by these rare conditions. Solid Biosciences offers a portfolio of gene therapy candidates, including SGT-001 for Duchenne muscular dystrophy and other therapies targeting catecholaminergic polymorphic ventricular tachycardia.

Notable affiliated individuals include the company's founders and key scientific advisors who are leaders in the field of genetic medicine. Solid Biosciences has attracted significant investment from prominent venture capital firms and industry partners. Key achievements include advancing their lead gene therapy candidate, SGT-001, through various stages of clinical trials. The company's impact lies in its potential to bring transformative treatments to patients with debilitating neuromuscular diseases, addressing unmet medical needs and improving patient outcomes.